Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a postbiotic soothe irritable bowel syndrome?

NCT ID NCT07699926

Symptom relief Sponsor: My Myracle Sdn.Bhd Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 15, 2026 · Updated 2 times

Summary

This study tests whether a daily postbiotic supplement called PosBion® can ease symptoms and improve quality of life in adults with irritable bowel syndrome (IBS). Participants take two sachets of the supplement each day for 12 weeks. Researchers measure changes in IBS symptoms, gut health, and related biomarkers using questionnaires and saliva samples.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PosBion® (inactivated Lactobacillus plantarum RS5 and RI11)
What this could lead to
If it works, this could offer a natural, over-the-counter option to help manage IBS symptoms and improve gut health.
What could go wrong
This is a small, single-arm, open-label study with no placebo group, so results may be biased or not generalizable. The supplement may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

55 people

The number who actually took part.

Started

Jan 2026

Finished

Jun 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Experienced one or more symptoms consistent with irritable bowel syndrome (IBS), including: * Stomach pain or abdominal cramps * Bloating * Excessive gas * Diarrhoea * Constipation (or alternating diarrhoea and constipation) * Mucus in stool * Urgency to defecate * Sensation of incomplete bowel evacuation * Willing and able to comply with all study procedures and scheduled visits. * Provided written informed consent before study participation. Exclusion Criteria: * History of chronic or serious medical conditions, including but not limited to diabetes mellitus, cardiovascular disease, chronic kidney disease, cancer, or chronic respiratory disease. * Current use of supplements intended to improve gut health. * Current use of antibiotics or antiviral medications. * Current use of probiotic, prebiotic, or postbiotic supplements. * Major surgery within the previous 6 months. * Pregnant or breastfeeding women. * Known allergy or hypersensitivity to any ingredient of the investigational product. * Any condition that, in the opinion of the investigators, could interfere with study participation, compliance, or interpretation of the study results.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gut health are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

digestive system disorder inflammatory bowel disease irritable bowel syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gut health IBD - inflammatory bowel disease IBS - irritable bowel syndrome

Contacts and locations

Locations

  • UCSI University

    Cheras, Kuala Lumpur, 56000, Malaysia

More trials for these conditions

Other studies related to the condition(s) this trial covers.